Domain I-IV of β2-glycoprotein I inhibits advanced glycation end product-induced angiogenesis by down-regulating vascular endothelial growth factor 2 signaling

Wang,Qian‑Qian; Zhou,Sai‑Jun; Meng,Zhen‑Xing; Wang,Jie; Chen,Rui; Lv,Lin; Li,Chun‑Jun; Yu,De‑Min; Yu,Pei

doi:10.3892/mmr.2014.2970

Domain I-IV of β2-glycoprotein I inhibits advanced glycation end product-induced angiogenesis by down-regulating vascular endothelial growth factor 2 signaling

Authors:
- Qian‑Qian Wang
- Sai‑Jun Zhou
- Zhen‑Xing Meng
- Jie Wang
- Rui Chen
- Lin Lv
- Chun‑Jun Li
- De‑Min Yu
- Pei Yu
View Affiliations

Affiliations: 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormones and Development (Ministry of Health), Metabolic Diseases Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, P.R. China
Published online on: November 18, 2014 https://doi.org/10.3892/mmr.2014.2970
Pages: 2167-2172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced glycation end products (AGEs) are a contributing factor in the angiogenesis that is characteristic of proliferative diabetic retinopathy. However, a previous study made a promising observation that domain I‑IV of β2‑glycoprotein I (DI‑IV) inhibits angiogenesis in human umbilical vein cells. The present study aimed to confirm the inhibition of AGE‑induced angiogenesis in retinal endothelial cells by DI‑IV and to investigate the potential underlying mechanisms. The RF/6A rhesus macaque choroid‑retinal vascular endothelial cell line was cultured in vitro and treated with AGEs in the presence or absence of different concentrations of DI‑IV. The proliferation, migration and tube formation of the RF/6A cells were evaluated using MTS assays, in vitro wound healing assays and in vitro Matrigel angiogenesis assays, respectively. The mRNA expression of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR) 2, VEGFR 1 and receptor for AGE (RAGE) were quantified by reverse transcription quantitative polymerase chain reaction. The expression of VEGFR‑1, VEGFR‑2 and the activation of protein kinase B (Akt) and extracellular signal‑regulated kinase (ERK) were also assessed by western blot analysis. The results indicated that AGEs promoted the migration, proliferation and tube formation of RF/6A cells in vitro (P<0.05), increased the expression of VEGF, VEGFR‑2 and RAGE (P<0.05) and increased the phosphorylation of Akt and ERK (P<0.05). DI‑IV inhibited the increase in VEGFR‑2 mRNA and protein, but did not inhibit the increase in VEGF or RAGE mRNAs. These results led to the conclusion that DI‑IV inhibited AGE‑induced angiogenesis in the RF/6A cells, which was accompanied by a downregulation in the expression of VEGFR‑2 and its downstream phosphatidylinosol 3‑kinase/Akt and mitogen‑activated protein kinase/ERK1/2 pathways. These findings provide further support towards the treatment of proliferative diabetic retinopathy by interventions that act via a mechanism similar to that of DI‑IV.

View Figures

View References

1	Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 378:31–40. 2011. View Article : Google Scholar : PubMed/NCBI
2	Fong DS, Aiello LP, Ferris FL and Klein R: Diabetic Retinopathy. Diabetes Care. 27:2540–2553. 2004. View Article : Google Scholar : PubMed/NCBI
3	Miller JW, Adamis AP and Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 13:37–50. 1997. View Article : Google Scholar : PubMed/NCBI
4	Goldin A, Beckman JA, Schmidt AM and Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 114:597–605. 2006. View Article : Google Scholar : PubMed/NCBI
5	Sato T, Wu X, Shimogaito N, et al: Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys. Eur J Nutr. 48:6–11. 2009. View Article : Google Scholar
6	Yamagishi S, Matsui T, Nakamura K, et al: Olmesartan blocks advanced glycation end products (AGE)-induced angiogenesis in vitro by suppressing receptor for AGE (RAGE) expression. Microvasc Res. 75:130–134. 2008. View Article : Google Scholar
7	De Groot PG and Meijers JC: β(2)-Glycoprotein I: evolution, structure and function. J Thromb Haemost. 9:1275–1284. 2011. View Article : Google Scholar : PubMed/NCBI
8	Passam FH, Qi JC, Tanaka K, Matthaei KI and Krilis SA: In vivo modulation of angiogenesis by beta 2 glycoprotein I. J Autoimmun. 35:232–240. 2010. View Article : Google Scholar : PubMed/NCBI
9	Yu P, Passam FH, Yu DM, Denyer G and Krilis SA: Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost. 6:1215–1223. 2008. View Article : Google Scholar : PubMed/NCBI
10	Yu P, Passam FH, Yu DM, Denyer G and Krilis SA: Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost. 6:1215–1223. 2008. View Article : Google Scholar : PubMed/NCBI
11	Beecken WD, Ringel EM, Babica J, et al: Plasmin-clipped beta (2)-glycoprotein-I inhibits endothelial cell growth by down-regulating cyclin A, B and D1 and up-regulating p21 and p27. Cancer Lett. 296:160–167. 2010. View Article : Google Scholar : PubMed/NCBI
12	Iverson GM, Victoria EJ and Marquis DM: Anti-beta2-glycoprotein I (beta2-GPI) autoantibodies recognize an epitope on the first domain of beta2-GPI. Proc Natl Acad Sci USA. 95:15542–15546. 1998. View Article : Google Scholar
13	Heo JW, Kim JH, Cho CS, et al: Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells. PLoS One. 7:e334562012. View Article : Google Scholar : PubMed/NCBI
14	Nichol D and Stuhlmann H: EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood. 119:1345–1352. 2012. View Article : Google Scholar :
15	Shibuya M: Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer. 1:1119–1123. 2010. View Article : Google Scholar
16	Huang Q and Sheibani N: High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol. 295:C1647–C1657. 2008. View Article : Google Scholar : PubMed/NCBI
17	Elayappan B, Ravinarayannan H, Pasha SP, Lee KJ and Gurunathan S: PEDF inhibits VEGF- and EPO-induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis. 12:313–324. 2009. View Article : Google Scholar
18	Lou DA and Hu FN: Specific antigen and organelle expression of a long-term rhesus endothelial cell line. In Vitro Cell Dev Biol. 23:75–85. 1987. View Article : Google Scholar : PubMed/NCBI
19	Du W, Yu W, Huang L, Zhao M and Li X: Ephrin-a4 is involved in retinal neovascularization by regulating the VEGF signaling pathway. Invest Ophthalmol Vis Sci. 53:1990–1998. 2012. View Article : Google Scholar : PubMed/NCBI
20	Amrite AC, Ayalasomayajula SP, Cheruvu NP and Kompella UB: Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 47:1149–1160. 2006. View Article : Google Scholar : PubMed/NCBI
21	Sun T, Cao H, Xu L, et al: Insulin-like growth factor binding protein-related protein 1 mediates VEGF-induced proliferation, migration and tube formation of retinal endothelial cells. Curr Eye Res. 36:341–349. 2011. View Article : Google Scholar : PubMed/NCBI
22	Grigsby JG, Parvathaneni K, Almanza MA, et al: Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation. J Ocul Pharmacol Ther. 27:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
23	Chen P, Zhao J and Gregersen H: Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats. Dig Dis Sci. 57:48–57. 2012. View Article : Google Scholar
24	Lee JJ, Hsiao CC, Yang IH, et al: High-mobility group box 1 protein is implicated in advanced glycation end products-induced vascular endothelial growth factor A production in the rat retinal ganglion cell line RGC-5. Mol Vis. 18:838–850. 2012.PubMed/NCBI
25	Shibuya M: Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) dignaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2:1097–1105. 2011. View Article : Google Scholar
26	Nakagawa H, Yasuda S, Matsuura E, et al: Nicked {beta}2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1–5) and attenuates its antiangiogenic property. Blood. 114:2553–2559. 2009. View Article : Google Scholar : PubMed/NCBI